文献速递鼻科

鼻内贝伐珠单抗治疗遗传性出血性毛细血管扩张症相关鼻出血的系统评价

Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review.
PubMed 文献 · Rhinology · 2018-01-01

局部给药(黏膜下注射或表面给药)在鼻出血持续时间、频率、严重程度及生活质量方面,与安慰剂或其他局部治疗相比均无显著影响。现有证据提示鼻内贝伐珠单抗对HHT相关鼻出血无明显疗效,但存在若干局限需进一步研究。

要点

  • 鼻内贝伐珠单抗局部给药对HHT相关鼻出血的持续时间、频率、严重程度及生活质量无显著改善。
  • 现有研究存在局限,尚不能完全排除局部贝伐珠单抗的疗效,需进一步研究。

核心结论

  • 现有证据提示鼻内贝伐珠单抗治疗对HHT患者的鼻出血无显著效果。
  • 研究存在若干局限,需进一步调查才能有把握地排除局部贝伐珠单抗作为HHT相关鼻出血有效疗法的可能。

研究设计与样本

  • 系统评价,遵循PRISMA指南,检索PubMed、MEDLINE和EMBASE数据库。
  • 纳入测量鼻内贝伐珠单抗治疗HHT患者鼻出血疗效的研究进行定性分析。

主要发现

  • 局部给药(黏膜下注射或表面给药)与安慰剂或其他局部治疗相比,对鼻出血持续时间无显著影响。
  • 局部给药与安慰剂或其他局部治疗相比,对鼻出血频率无显著影响。
  • 局部给药与安慰剂或其他局部治疗相比,对鼻出血严重程度无显著影响。
  • 局部给药与安慰剂或其他局部治疗相比,对生活质量无显著影响。

临床怎么用

  • 基于现有证据,鼻内贝伐珠单抗局部治疗不宜作为HHT相关鼻出血的常规有效疗法推荐。
  • 临床决策时应结合研究局限性,个体化评估并关注进一步研究证据。

局限性

  • 原文指出存在若干局限,需进一步研究才能有把握地排除局部贝伐珠单抗对HHT相关鼻出血的疗效。
  • 具体局限内容原文摘要未详述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hereditary haemorrhagic telangiectasia (HHT) remains a difficult disease for the ENT specialist to manage. Affected patients often report recurrent epistaxis as the most debilitating symptom. The pathogenesis of the disease is due to genetic mutations affecting angiogenesis. For this reason, the anti-angiogenic therapy bevacizumab has gained popularity in the local treatment of epistaxis in patients with HHT. OBJECTIVE: A systematic review of the efficacy of bevacizumab in local treatment of epistaxis in patients with HHT based on epistaxis duration, frequency, severity and impact on quality of life. METHODS: A systematic search was performed using the PubMed, MEDLINE and EMBASE databases. The Preferred Items for Systematic Reviews and Meta-Analyses guidelines were followed. Studies that measured the efficacy of intranasal bevacizumab treatment of epistaxis in patients with HHT were included for qualitative analysis. RESULTS: Thirteen studies (four randomised controlled trials, three prospective studies, three retrospective studies, one case series and two case reports) with a total of 357 patients were included. Local administration (either by submucosal injection or topically) did not have a significant impact on epistaxis duration, frequency, severity or quality of life compared to placebo or other local treatments. CONCLUSIONS: The available evidence suggests that intranasal bevacizumab treatment does not have a significant effect on epistaxis in patients with HHT. There are several limitations that require further investigation to confidently rule out local bevacizumab as an effective therapy in HHT related epistaxis.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Stokes P, Rimmer J. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review. Rhinology. 2018. PMID: 29166422. doi:10.4193/Rhin17.166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。